Recent Updates
Recently added Catalysts

Emfilermin, recombinant human leukemia inhibitory factor

Phase 1/2

Infertility Implantation Failure | Small Molecules | Other |Merck KGaA|Trials Updated: Jan 4, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment200

FDA Designations

No designations recorded

Emfilermin, recombinant human leukemia inhibitory factor clinical trials

Emfilermin, recombinant human leukemia inhibitory factor · 2 trials · 1 indication

Phase 1/2 2
NCT00504608A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation FailureInfertility Implantation Failure
COMPLETED150 Analytics
NCT00504530r-hLIF for Improving Embryo Implantation in IVFInfertility Implantation Failure
COMPLETED50 Analytics
PHASE1/PHASE2COMPLETED
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure
Infertility Implantation Failure
NCT00504608150
Unlock trial analytics
PHASE1/PHASE2COMPLETED
r-hLIF for Improving Embryo Implantation in IVF
Infertility Implantation Failure
NCT0050453050
Unlock trial analytics

Study Endpoints

Primary Endpoints

Improvement of embryo implantation and safety
Various

Secondary Endpoints

Implantation rate, all pregnancy rateand number of live births.
Various
Secondary endpoints were implantation rate, proportion of patients with biochemical pregnancy and the number of live births.
various
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 37 Years
SexFEMALE
Healthy VolunteersNo

Inclusion Criteria: 1. Pre-menopausal woman aged 21-37 years inclusive at time of consent. 2. Infertile woman justifying IVF-ET treatment and wishing to conceive. 3. The presence of both ovaries. 4. Current body mass index (BMI) of ≥ 20 \& ≤ 30 kg/m2 5. Early follicular phase (cycle day 2-5) serum ...

Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Merck KGaA (MKGAF)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track